Developing innovative ocular solutions
Nicox is an international ophthalmology company developing innovative therapeutics to help maintain vision and improve ocular health.
We plan to keep the maximum of options open for the company by maintaining rights to our novel therapeutics for eye diseases in key territories, such as the U.S. and Europe, as we create value by advancing their development, maintaining the potential for direct marketing, licensing for certain territories and growth through strategic transactions.

Our ophthalmic pipeline includes two programs in clinical development, NCX 470 targeting glaucoma and NCX 4251 targeting dry eye disease. We also have two products which are commercialized in the U.S., VYZULTA® (latanoprostene bunod ophthalmic solution) 0.024% and ZERVIATE® (cetirizine ophthalmic solution) 0.24%, for use in patients with open-angle glaucoma and ocular allergic conjunctivitis, respectively, and which are being rolled-out in territories outside of the U.S. through partnerships.